Thiazolidinediones News and Research

RSS

Thiazolidinediones are adjunctive therapies for diabetes mellitus (type 2) and related diseases.

Abscisic acid has anti-inflammatory effects in the lungs and gut

Building on previous work with the botanical abscisic acida, researchers in the Nutritional Immunology and Molecular Medicine Laboratory (NIMML) have discovered that abscisic acid has anti-inflammatory effects in the lungs as well as in the gut.

19 Jul 2012

Diabetes drug raises bladder cancer risk

Data from a robust meta-analysis have reinforced concerns about the link between the Type 2 diabetes drug, pioglitazone, and bladder cancer.

10 Jul 2012

Pioglitazone may raise bladder cancer risk

Study evidence supports a link between thiazolidinedione use, particularly pioglitazone, and bladder cancer in patients with Type 2 diabetes, Canadian researchers report.

9 Jul 2012

Pioglitazone may raise bladder cancer risk

Study evidence supports a link between thiazolidinedione use, particularly pioglitazone, and bladder cancer in patients with Type 2 diabetes, Canadian researchers report.

9 Jul 2012

Thiazolidinedione drugs linked with increased risk of DME in patients with Type 2 diabetes

Treatment with glucose-lowering thiazolidinedione drugs in patients with Type 2 diabetes appears to be associated with an increased risk of diabetic macular edema (a complication that may affect vision) at 1-year and 10-year follow-up evaluations, according to a report published Online First by Archives of Internal Medicine, a JAMA Network publication.

12 Jun 2012

Researchers identify new mitochondrial protein complex linked with type 2 diabetes

Researchers at Metabolic Solutions Development Company, LLC (MSDC) have identified a mitochondrial protein complex through which anti-diabetic drugs exert their insulin sensitizing effects when used to treat patients diagnosed with type 2 diabetes.

11 Jun 2012

Increased risk of bladder cancer linked to diabetes drug

Pioglitazone - a drug used to treat type 2 diabetes - is associated with an increased risk of bladder cancer, finds a study published on bmj.com today.

1 Jun 2012

NCoR deficiency may pump up muscles and prevent diabetes

Two independent studies in the Nov. 11 issue of the journal Cell, a Cell Press publication, suggest a common way to pump up muscles and prevent diabetes. The key is a molecule required for fine-tuning metabolism by selectively and subtly modifying core metabolic programs.

11 Nov 2011

Byetta combination with insulin glargine gets FDA nod in type 2 diabetes

The US Food and Drugs Administration (FDA) has approved Byetta (exenatide) injection as add-on treatment for use with insulin glargine, together with exercise and diet for diabetes type 2 patients who are not responding well enough to glargine alone. Byetta's add-on therapy is for those on glargine with metformin and/or a TZD (thiazolidinedione) or without.

20 Oct 2011

Researchers create powerful anti-diabetic prototype drugs with lesser side effects

Researchers from Dana-Farber Cancer Institute in Boston and the Scripps Research Institute in Jupiter, Fla., report they have created prototype drugs having powerful anti-diabetic effects, yet apparently free - at least in mice - of dangerous side effects plaguing some current diabetes medications.

9 Sep 2011

Takeda resubmits alogliptin and fixed-dose combination therapy NDA to FDA

Takeda Pharmaceutical Company Limited announced today that Takeda Global Research & Development Center, Inc., resubmitted two New Drug Applications to the United States Food and Drug Administration for alogliptin and the fixed-dose combination therapy alogliptin/pioglitazone, which combines alogliptin with pioglitazone in a single tablet.

26 Jul 2011

New biological insights into fat tissue

For better or worse, a popular class of anti-diabetic drugs does more than lower blood sugar. One known as rosiglitazone has been in the spotlight for its possible link to increased cardiovascular events, but it also seems to come with unexplained vascular benefits and an unwelcome tendency for weight gain.

6 Jul 2011

Key regulator of fat cell development may provide a target for obesity and diabetes drugs

New research by scientists at The Scripps Research Institute and collaborating institutions has identified a key regulator of fat cell development that may provide a target for obesity and diabetes drugs.

8 Apr 2011

TZDs might serve as new agents for addiction treatment

Thiazolidinediones are a class of medications that are commonly prescribed to treat type-2 diabetes, while fibrates are a structurally-related class of medications that are prescribed to modulate lipid levels in both diabetic and non-diabetic patients to help reduce the risk of cardiovascular disease.

6 Apr 2011

Type 2 diabetes drug less likely to cause weight gain, raise cholesterol levels

An inexpensive type 2 diabetes drug that has been around for more than 15 years works just as well and has fewer side effects than a half-dozen other, mostly newer and more expensive classes of medication used to control the chronic disease, new Johns Hopkins research suggests.

15 Mar 2011

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

Merck today announced that the New Drug Application (NDA) for the Company's investigational extended-release formulation of JANUMET for type 2 diabetes has been accepted for standard review by the U.S. Food and Drug Administration (FDA). The Company is also moving forward as planned with regulatory filings in countries outside the United States.

12 Jan 2011

VYTORIN reduces major vascular events in patients with chronic kidney disease

In a new investigational study of VYTORIN, the cholesterol-lowering medicine from Merck, VYTORIN 10/20 mg reduced the incidence of first major vascular events defined as non-fatal heart attacks or cardiac death, stroke or any revascularization procedure by a highly statistically significant 16.1 percent compared to placebo, Study of Heart and Renal Protection study involved more than 9,000 patients who, on average, had advanced or end-stage chronic kidney disease (CKD)

22 Nov 2010

Santarus announces commercial U.S. launch of CYCLOSET for type 2 diabetes mellitus

Santarus, Inc., a specialty biopharmaceutical company, today announced the commercial U.S. launch of CYCLOSET (bromocriptine mesylate) tablets. CYCLOSET is a prescription drug approved by the U.S. Food and Drug Administration (FDA) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus both as monotherapy and in combination with other oral antidiabetic agents.

15 Nov 2010

Metabolon receives patent for biomarkers to determine PPAR-affecting drugs

Metabolon, Inc., leaders in global metabolomics, biomarker discovery and biochemical analysis, announced today the grant of US Patent 7,807,138 entitled "Biomarkers of Metabolic Responses to Hepatic Drugs". The USPTO awarded the patent to Metabolon on October 5, 2010. This is the 13th patent issued to Metabolon and the second in its portfolio of biomarker patents.

21 Oct 2010

ChemoCentryx presents CCX140 clinical data at EASD

ChemoCentryx, Inc., today announced that it reported positive preclinical and Phase I study results at the European Association for the Study of Diabetes (EASD). CCX140, a novel, orally bioavailable small molecule antagonist of the chemokine receptor CCR2, improved metabolic function while significantly reducing inflammatory macrophages found in adipose tissue in an animal model, and was well tolerated in Phase I clinical trials.

21 Sep 2010